Join Growin Stock Community!

Purple biotech ltd.PPBT.US Overview

US StockHealthcare
(No presentation for PPBT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PPBT AI Insights

PPBT Overall Performance

PPBT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PPBT Recent Performance

908.14%

Purple biotech ltd.

0.05%

Avg of Sector

-0.31%

S&P500

PPBT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PPBT Key Information

PPBT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PPBT Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Price of PPBT

PPBT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PPBT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
58.08
PB Ratio
1.22
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
58.08
PB Ratio
1.22
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PPBT's latest earnings report released?

    The most recent financial report for Purple biotech ltd. (PPBT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PPBT's short-term business performance and financial health. For the latest updates on PPBT's earnings releases, visit this page regularly.

  • Where does PPBT fall in the P/E River chart?

    According to historical valuation range analysis, Purple biotech ltd. (PPBT)'s current price-to-earnings (P/E) ratio is 20.12, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much debt does PPBT have?

    As of the end of the reporting period, Purple biotech ltd. (PPBT) had total debt of 256K, with a debt ratio of 0.01. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PPBT have?

    At the end of the period, Purple biotech ltd. (PPBT) held Total Cash and Cash Equivalents of 9.59M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PPBT's EPS continuing to grow?

    According to the past four quarterly reports, Purple biotech ltd. (PPBT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PPBT?

    Purple biotech ltd. (PPBT)'s Free Cash Flow (FCF) for the period is -1.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 67.86% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PPBT?

    The latest valuation data shows Purple biotech ltd. (PPBT) has a Price-To-Earnings (PE) ratio of 20.12 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.